These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 30359146)

  • 1. Capacitive hyperthermia as an alternative to brachytherapy in DNA damages of human prostate cancer cell line (DU-145).
    Mahdavi SR; Janati Esfahani A; Khoei S; Bakhshandeh M; Rajabi A
    Int J Radiat Biol; 2019 Feb; 95(2):193-200. PubMed ID: 30359146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Radiofrequency Hyperthermia in The Radiosensitization of A Human Prostate Cancer Cell Line.
    Janati Esfahani A; Mahdavi SR; Shiran MB; Khoei S
    Cell J; 2017; 19(Suppl 1):86-95. PubMed ID: 28580312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced DNA Damages of Human Prostate Cancer Cells Induced by Radiofrequency Capacitive Hyperthermia Pre- and Post X-rays: 6 MV versus 15 MV.
    Mahdavi SR; Janati Esfahani A; Shiran MB; Khoei S; Estiri N
    Cell J; 2017; 19(Suppl 1):79-85. PubMed ID: 28580311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base.
    Amini A; Jones B; Jackson MW; Yeh N; Waxweiler TV; Maroni P; Kavanagh BD; Raben D
    J Urol; 2016 May; 195(5):1453-1458. PubMed ID: 26576709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
    Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferential radiosensitization of human prostatic carcinoma cells by mild hyperthermia.
    Ryu S; Brown SL; Kim SH; Khil MS; Kim JH
    Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):133-8. PubMed ID: 12118542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thermometry of interstitial hyperthermia given as an adjuvant to brachytherapy for the treatment of carcinoma of the prostate.
    Prionas SD; Kapp DS; Goffinet DR; Ben-Yosef R; Fessenden P; Bagshaw MA
    Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):151-62. PubMed ID: 8270436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
    King CR; DiPetrillo TA; Wazer DE
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
    Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
    Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
    Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
    Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the relationship between prescribed dose and dosimetric advantage of real-time intraoperatively built custom-linked seeds in iodine-125 prostate brachytherapy.
    Hirose K; Aoki M; Sato M; Akimoto H; Hashimoto Y; Imai A; Kamimura N; Kawaguchi H; Hatayama Y; Fujioka I; Tanaka M; Ohyama C; Takai Y
    Radiat Oncol; 2017 Dec; 12(1):192. PubMed ID: 29191234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us?
    Wang JZ; Li XA; Yu CX; DiBiase SJ
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1101-8. PubMed ID: 14575842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis.
    Kalakota K; Rakhno E; Pelizzari CA; Jani AB; Liauw SL
    Brachytherapy; 2010; 9(2):131-6. PubMed ID: 19853533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications.
    Moulton CR; House MJ; Lye V; Tang CI; Krawiec M; Joseph DJ; Denham JW; Ebert MA
    Radiat Oncol; 2016 Oct; 11(1):144. PubMed ID: 27799048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
    Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer.
    Khor R; Duchesne G; Tai KH; Foroudi F; Chander S; Van Dyk S; Garth M; Williams S
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):679-85. PubMed ID: 22954770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.